BioMarin Pharmaceutical (HAM:BM8) FCF Margin %: 26.07% (As of Mar. 2026)


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
79 GF Score
Price €48.79
GF Value €72.11
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical FCF Margin %?

BioMarin Pharmaceutical HAM:BM8 -3.65% 79 FCF Margin % is 26.07% as of Mar. 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 79/100 and a GF Value™ of €72.11. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, BioMarin Pharmaceutical ranks better than 90.72% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioMarin Pharmaceutical's Free Cash Flow for the three months ended in Mar. 2026 was €173 Mil. BioMarin Pharmaceutical's Revenue for the three months ended in Mar. 2026 was €663 Mil. Therefore, BioMarin Pharmaceutical's FCF Margin % for the quarter that ended in Mar. 2026 was 26.07%.

As of today, BioMarin Pharmaceutical's current FCF Yield % is 6.66%.

The historical rank and industry rank for BioMarin Pharmaceutical's FCF Margin % or its related term are showing as below:

HAM:BM8' s FCF Margin % Range Over the Past 10 Years
Min: -33.69   Med: -0.34   Max: 23.4
Current: 23.4

During the past 13 years, the highest FCF Margin % of BioMarin Pharmaceutical was 23.40%. The lowest was -33.69%. And the median was -0.34%.

HAM:BM8's FCF Margin % is ranked better than
90.72% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs HAM:BM8: 23.40

BioMarin Pharmaceutical FCF Margin % Related Terms

BioMarin Pharmaceutical FCF Margin % Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical FCF Margin % Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.04 2.12 2.13 16.66 22.26

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.15 20.34 43.15 6.47 26.07

HAM:BM8 vs ARWR, MDGL, CYTK: FCF Margin % Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMarin Pharmaceutical FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's FCF Margin % falls into.


HAM:BM8
79GF Score
BioMarin Pharmaceutical Inc HAM:BM8
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioMarin Pharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=612.334/2750.95
=22.26 %

BioMarin Pharmaceutical's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=172.765/662.77
=26.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 26.07% mean?
BioMarin Pharmaceutical (HAM:BM8) has a FCF Margin % of 26.07% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioMarin Pharmaceutical and its competitors. According to the industry distribution chart, BioMarin Pharmaceutical ranks #89 out of 959 companies in the Biotechnology industry, placing it in the top 9.3%.
Is BioMarin Pharmaceutical's FCF Margin % too high?
BioMarin Pharmaceutical's current FCF Margin % is 26.07%. Based on the distribution chart, BioMarin Pharmaceutical ranks #89 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's FCF Margin % compare to ARWR and MDGL?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #89 out of 959 companies for FCF Margin %. This places BioMarin Pharmaceutical in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current FCF Margin % is 26.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current FCF Margin % of 26.07%. The stock's GF Value™ is €72.11, compared to a current price of €48.79 — trading 32.3% below its estimated fair value. The current FCF Margin % is 26.07%. BioMarin Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current FCF Margin % is 26.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €48.79 is trading 32.3% below its estimated GF Value™ of €72.11.

Key valuation signals for HAM:BM8:

  • FCF Margin %: 26.07%
  • GF Value™: €72.11 vs. price of €48.79 (32.3% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for HAM:BM8

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.79
Price
€72.11
GF Value